TCG Crossover Management, LLC
- SEC CIK
- 0001839948
- Latest filing
- Aug 14, 2026
Holdings in Q4 2025
Holdings as of Dec 31, 2025, filed Feb 17, 2026. Long positions only; changes compare share counts with Q3 2025.
- Positions
- 43
- +3 vs. Q3 2025
- Portfolio value
- $3.02B
- +$988.8M (+48.6%) vs. Q3 2025
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| ABVXAbivax S.A. | SPONSORED ADS | 7,111,596 | $959.0M | 31.7% | 00.0% | Unchanged | History |
| COGTCogent Biosciences, Inc. | COM | 5,868,162 | $208.4M | 6.9% | −930,000−13.7% | Reduced | History |
| CGONCG Oncology, Inc. | COM | 3,670,206 | $152.4M | 5.0% | 00.0% | Unchanged | History |
| TNGXTango Therapeutics, Inc. | COM | 12,762,094 | $113.1M | 3.7% | +4,225,898+49.5% | Added | History |
| CNTACentessa Pharmaceuticals plc | SPONSORED ADS | 4,286,480 | $107.2M | 3.5% | +1,150,000+36.7% | Added | History |
| DYNDyne Therapeutics, Inc. | COM | 4,615,144 | $90.3M | 3.0% | 00.0% | Unchanged | History |
| RAPTRAPT Therapeutics, Inc. | COM NEW | 2,582,408 | $87.5M | 2.9% | +946,133+57.8% | Added | History |
| TYRATyra Biosciences, Inc. | COM | 2,898,103 | $76.2M | 2.5% | 00.0% | Unchanged | History |
| AMLXAmylyx Pharmaceuticals, Inc. | COM | 6,243,812 | $75.4M | 2.5% | 00.0% | Unchanged | History |
| SVRASavara Inc | COM | 12,362,205 | $74.5M | 2.5% | 00.0% | Unchanged | History |
| GLUEMonte Rosa Therapeutics, Inc. | COM | 4,622,151 | $72.5M | 2.4% | +4,622,151 | New | History |
| OCULOcular Therapeutix, Inc | COM | 5,740,231 | $69.7M | 2.3% | −377,001−6.2% | Reduced | History |
| DNTHDianthus Therapeutics, Inc. | COM | 1,676,624 | $69.1M | 2.3% | 00.0% | Unchanged | History |
| EYPTEyePoint, Inc. | COM NEW | 3,572,335 | $65.3M | 2.2% | 00.0% | Unchanged | History |
| GPCRStructure Therapeutics Inc. | SPONSORED ADS | 920,857 | $64.0M | 2.1% | −142,143−13.4% | Reduced | History |
| SYRESpyre Therapeutics, Inc. | COM NEW | 1,900,582 | $62.3M | 2.1% | +800,000+72.7% | Added | History |
| FULCFulcrum Therapeutics, Inc. | COM | 5,250,000 | $59.4M | 2.0% | 00.0% | Unchanged | History |
| LQDALiquidia Corp | COM NEW | 1,710,084 | $59.0M | 2.0% | 00.0% | Unchanged | History |
| BHVNBiohaven Ltd. | COM | 4,631,317 | $52.3M | 1.7% | +4,631,317 | New | History |
| IMVTImmunovant, Inc. | COM | 1,660,933 | $42.2M | 1.4% | +1,660,933 | New | History |
| KODKodiak Sciences Inc. | COM | 1,445,538 | $40.4M | 1.3% | +300,000+26.2% | Added | History |
| ADCTADC Therapeutics SA | SHS | 11,390,175 | $40.2M | 1.3% | +10,000,000+719.3% | Added | History |
| LBRXLB Pharmaceuticals Inc | COM SHS | 1,745,015 | $38.8M | 1.3% | −10.0% | Reduced | History |
| XNCRXencor Inc | COM | 2,452,138 | $37.5M | 1.2% | 00.0% | Unchanged | History |
| RVMDRevolution Medicines, Inc. | COM | 436,473 | $34.8M | 1.2% | 00.0% | Unchanged | History |
| AGIOAgios Pharmaceuticals, Inc. | COM | 1,181,841 | $32.2M | 1.1% | −248,200−17.4% | Reduced | History |
| ARVNArvinas, Inc. | COM | 2,666,216 | $31.6M | 1.0% | +1,048,851+64.8% | Added | History |
| RLAYRelay Therapeutics, Inc. | COM | 3,220,186 | $27.2M | 0.9% | +1,409,835+77.9% | Added | History |
| JANXJanux Therapeutics, Inc. | COM | 1,789,617 | $24.7M | 0.8% | +1,789,617 | New | History |
| TRDAEntrada Therapeutics, Inc. | COM | 2,088,392 | $21.5M | 0.7% | +1,503,437+257.0% | Added | History |
| MBXMBX Biosciences, Inc. | COM | 650,000 | $20.5M | 0.7% | 00.0% | Unchanged | History |
| UPBUpstream Bio, Inc. | COM | 743,886 | $20.2M | 0.7% | −1,373,217−64.9% | Reduced | History |
| SLNSilence Therapeutics plc | ADS | 3,033,560 | $18.4M | 0.6% | 00.0% | Unchanged | History |
| URGNUroGen Pharma Ltd. | COM | 717,347 | $16.8M | 0.6% | 00.0% | Unchanged | History |
| ALECAlector, Inc. | COM | 10,000,000 | $15.6M | 0.5% | +10,000,000 | New | History |
| MNPRMonopar Therapeutics | COM NEW | 141,915 | $9.27M | 0.3% | −11,085−7.2% | Reduced | History |
| AVTXAvalo Therapeutics, Inc. | COM NEW | 483,000 | $8.77M | 0.3% | 00.0% | Unchanged | History |
| MAZEMaze Therapeutics, Inc. | COM | 173,816 | $7.20M | 0.2% | +173,816 | New | History |
| MIRMMirum Pharmaceuticals, Inc. | COM | 62,049 | $4.90M | 0.2% | +62,049 | New | History |
| LONALeonaBio, Inc. | COM | 464,398 | $3.35M | 0.1% | +464,398 | New | History |
| KRROKorro Bio, Inc. | COM | 416,301 | $3.33M | 0.1% | 00.0% | Unchanged | History |
| VTYXVentyx Biosciences, Inc. | COM | 316,195 | $2.86M | 0.1% | 00.0% | Unchanged | History |
| VTGNVistagen Therapeutics, Inc. | COM | 2,676,580 | $1.77M | 0.1% | 00.0% | Unchanged | History |
Sold out since Q3 2025 (5)
Positions held at the end of Q3 2025 that are gone from this filing.
| Security | Class | Shares in Q3 2025 | Value in Q3 2025 | % of portfolio in Q3 2025 | History |
|---|---|---|---|---|---|
| TRMLTourmaline Bio, Inc. | COM | 1,311,783 | $62.7M | 3.1% | History |
| IRONDisc Medicine, Inc. | COM | 465,257 | $30.7M | 1.5% | History |
| ATXSAstria Therapeutics, Inc. | COM | 2,761,861 | $20.1M | 1.0% | History |
| ADVMAdverum Biotechnologies, Inc. | COM NEW | 1,668,174 | $7.56M | 0.4% | History |
| PEPGPepGen Inc. | COM | 1,200,000 | $5.54M | 0.3% | History |